A cocktail of long-acting antibodies given intramuscularly can potentially diminish the risk of developing symptomatic COVID-19 in high-risk unvaccinated patients, stated AstraZeneca.

Data from a phase III trial has revealed that AZD7442 (tixagevimab and cilgavimab) administered as pre-exposure prophylaxis significantly decreased the risk of developing COVID-19 symptoms by 77% compared to placebo, meeting the trial′s primary endpoint. The company also stated that there were no cases of severe COVID-19 or COVID-19-related deaths in the intervention group while there were three cases of severe COVID-19 and two deaths in the placebo group. The treatment was well-tolerated and adverse events were balanced between the groups. Of note, around 75% of the trial participants had comorbidities. The company intends to submit the full results for peer-reviewed publication, while trials continue for treatment as well as prevention… (Medpage Today)